Treadwell Therapeutics, Inc
3 clinical trials · Sponsor
◉ Watch Treadwell Therapeutics, Inc
| Record | Firm | Date |
|---|---|---|
| CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer (NCT05251714) | Treadwell Therapeutics, Inc | 2022-05-27 |
| A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (NCT04730258) | Treadwell Therapeutics, Inc | 2021-04-16 |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies (NCT04521413) | Treadwell Therapeutics, Inc | 2020-08-31 |
Track Treadwell Therapeutics, Inc automatically
Every clearance here is in the API, with alerts when new ones post.